Skip to main content
. Author manuscript; available in PMC: 2018 Mar 13.
Published in final edited form as: Aliment Pharmacol Ther. 2017 Mar 8;45(9):1201–1212. doi: 10.1111/apt.14021

Figure 4.

Figure 4

Monthly HCV regimens initiated from January 2013 to December 2015 by HCV regimen (A) and clinical characteristics (B and C). After increased funding became available in October 2014, monthly rates increased dramatically from October 2014 to March 2015. After funding began to become exhausted, treatment numbers declined, particularly among patients without cirrhosis. Congress passed legislation for HCV treatment in August and September 2015, followed by a dramatic increase in treatment initiations, particularly among patients without cirrhosis.

PEG = pegylated-interferon,

SOF = sofosbuvir,

LDV/SOF = ledipasvir/sofosbuvir,

PrOD = paritaprevir/ritonavir/ombitasvir/dasabuvir